The Effects of Oxybutynin on Urinary Symptoms in Children with Williams-Beuren Syndrome

Imagem de Miniatura
Arquivos
art_SAMMOUR_The_Effects_of_Oxybutynin_on_Urinary_Symptoms_in_2012_eng.pdf (411.8 KB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
BESSA JR., Jose de
Citação
JOURNAL OF UROLOGY, v.188, n.1, p.253-257, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose: Williams-Beuren syndrome is a genomic disorder caused by a hemizygous contiguous gene deletion on chromosome 7q11.23. Lower urinary tract symptoms are common in children with Williams-Beuren syndrome. However, there are few data on the management of voiding symptoms in this population. We report our experience using oxybutynin to treat urinary symptoms in children with Williams-Beuren syndrome. Materials and Methods: We prospectively analyzed 42 patients with Williams-Beuren syndrome and significant lower urinary tract symptoms due to detrusor overactivity diagnosed on urodynamics in a 12-week, open-label study. Urological assessment included symptomatic evaluation, the impact of lower urinary tract symptoms on quality of life, frequency-volume chart, urodynamics and urinary tract sonography. After 12 weeks of treatment with 0.6 mg/kg oxybutynin per day given in 3 daily doses, patients were assessed for treatment efficacy and side effects. Results: A total of 17 girls and 19 boys completed medical therapy and were assessed at 12 weeks. Mean +/- SD patient age was 9.2 +/- 4.3 years (range 3 to 18). The most common urinary complaint was urgency, which occurred in 31 patients (86.1%), followed by urge incontinence, which was seen in 29 (80.5%). Compared to baseline, urinary symptoms were substantially improved. The negative impact of storage symptoms on quality of life was significantly decreased from a mean +/- SD of 3.3 +/- 1.7 to 0.5 +/- 0.9 (p <0.001). Mean +/- SD maximum urinary flow improved from 14.2 +/- 15.0 to 20.5 +/- 6.4 ml per second (p <0.001). Conclusions: A total of 12 weeks of therapy with 0.6 mg/kg oxybutynin daily resulted in improvement of lower urinary tract symptoms, quality of life and maximum flow rate in most patients with Williams-Beuren syndrome.
Palavras-chave
lower urinary tract symptoms, oxybutynin, urination disorders, urodynamics, Williams syndrome
URI
https://observatorio.fm.usp.br/handle/OPI/318
Referências
  1. Ayan S, 2007, J UROLOGY, V177, P2325, DOI 10.1016/j.juro.2007.02.001
  2. Aydogdu O, 2010, EUR J PEDIATR, V169, P431, DOI 10.1007/s00431-009-1042-9
  3. BARRY MJ, 1992, J UROLOGY, V148, P1549
  4. BORG I, 1995, J MED GENET, V32, P692, DOI 10.1136/jmg.32.9.692
  5. Cartwright PC, 2009, J UROLOGY, V182, P1548, DOI 10.1016/j.juro.2009.06.058
  6. Curran MJ, 2000, J UROLOGY, V163, P574, DOI 10.1016/S0022-5347(05)67934-7
  7. Diokno A, 2006, UROL CLIN N AM, V33, P439, DOI 10.1016/j.ucl.2006.06.003
  8. Duel BP, 2003, J UROLOGY, V170, P1521, DOI 10.1097/01.ju.0000091219.46560.7b
  9. Ebert AK, 2008, UROLOGE, V47, P337, DOI 10.1007/s00120-007-1614-0
  10. ELEJALDE BR, 1979, AM J MED GENET, V3, P97, DOI 10.1002/ajmg.1320030114
  11. EWART AK, 1993, NAT GENET, V5, P11, DOI 10.1038/ng0993-11
  12. Franco I, 2005, J UROLOGY, V173, P221, DOI 10.1097/01.ju.0000147813.28822.d2
  13. Gosch A, 1997, DEV MED CHILD NEUROL, V39, P527
  14. Mobbs D, 2007, BIOL PSYCHIAT, V62, P256, DOI 10.1016/j.biopsych.2006.05.041
  15. MORRIS CA, 1988, J PEDIATR, V113, P318, DOI 10.1016/S0022-3476(88)80272-5
  16. Munding M, 2001, J UROLOGY, V165, P926, DOI 10.1016/S0022-5347(05)66576-7
  17. Neveus T, 2006, J UROLOGY, V176, P314, DOI 10.1016/S0022-5347(06)00305-3
  18. Nijman RJM, 2005, J UROLOGY, V173, P1334, DOI 10.1097/01.ju.0000155441.55271.cd
  19. Nijman RJM, 2004, UROLOGY, V63, P45, DOI 10.1016/j.urology.2003.11.004
  20. OCHOA B, 1992, J UROLOGY, V148, P580
  21. PANKAU R, 1994, AM J MED GENET, V52, P285, DOI 10.1002/ajmg.1320520307
  22. Sammour ZM, 2006, J UROLOGY, V175, P1472, DOI 10.1016/S0022-5347(05)00666-X
  23. Schulman SL, 1996, J PEDIATR, V129, P466, DOI 10.1016/S0022-3476(96)70086-0
  24. Silver FH, 2001, CRIT REV BIOMED ENG, V29, P279
  25. Silveri M, 2004, J UROLOGY, V171, P2651, DOI 10.1097/01.ju.0000110885.26017.b0
  26. Smith JF, 2007, J UROLOGY, V178, P656, DOI 10.1016/j.juro.2007.04.007
  27. Sommer BR, 2005, J UROLOGY, V173, P2125, DOI 10.1097/01.ju.0000157685.83573.79
  28. SZABO L, 1995, BRIT J UROL, V76, P16, DOI 10.1111/j.1464-410X.1995.tb07824.x
  29. van Gool J D, 1992, Scand J Urol Nephrol Suppl, V141, P58

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - HC/IMREA
Artigos e Materiais de Revistas Científicas - HC/IOT
Artigos e Materiais de Revistas Científicas - LIM/36
Carregar mais